Asthma Disease Global Market Insights: Growth Drivers, Size & Forecasts to 2029

Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.

What Is the Forecasted Market Growth Rate of the Asthma Disease Industry?
The value of the asthma disease market has witnessed significant growth in the last few years. The market will expand from $24.63 billion in 2024 to $25.93 billion in 2025, growing at a compound annual growth rate (CAGR) of 5.3% . The spurt in growth during the historical period can be connected to an increased occurrence of asthma among city dwellers, escalating levels of pollution in industrial areas, heightened awareness about the symptoms and diagnosis of asthma, a rising trend in the usage of corticosteroids and bronchodilators, along with an expansion of healthcare accessibility in emergent countries.

How Will the Asthma Disease Market Size Evolve From 2025 to 2029?
The market for asthma disease management is projected to experience robust growth in the coming years, with the size anticipated to rise to $31.56 billion by 2029, growing at a compound annual growth rate (CAGR) of 5.0%. Key factors contributing to this projected growth during the forecast period include the growing preference for biologic solutions for severe asthma treatment, an escalating demand for personalized medicine, uptick in asthma-focused research funding, the rise of digital health and remote monitoring tools adoption, along with the expansion of telemedicine services for asthma management. Moving forward, the forecast period is set to witness certain trends like enhanced biologic therapies for severe asthma, state-of-the-art smart inhaler technologies, AI-based asthma monitoring tools' development, innovative personalized treatment strategies for asthma, and the emergence of digital health platforms for distant asthma management.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/asthma-disease-global-market-report

What Are the Main Growth Drivers in the Asthma Disease Market Today?
The escalating incidence of respiratory ailments is anticipated to drive the expansion of the asthma disease market in the future. These respiratory conditions encompass a variety of lung and breathing issues, such as chronic obstructive pulmonary disease (COPD), bronchitis, and notably, asthma. The surge in these diseases can be attributed to the irritation and inflammation of airways due to particulate matter and nitrogen oxides, resulting in exacerbated asthma conditions and breathing difficulties. Such respiratory illnesses can instigate inflammation and the remodeling of airways, which can trigger or worsen the symptoms of asthma. The National Library of Medicine, a U.S based national library, reported in December 2023 that by 2050, it is predicted that COPD cases in low and middle-income nations will outnumber those in high-income nations. Sub-Saharan Africa, in particular, is expected to see a 59% surge and emerge as the global leader in terms of COPD prevalence and cases by 2040. Hence, the rising incidence rate of respiratory ailments is propelling the growth of the asthma disease market.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25701&type=smp

Which Asthma Disease Market Segment Is Expected to Lead Through 2029?
The asthma disease market covered in this report is segmented -

1) By Treatment Type: Controller Medications, Rescue Medications, Biologics, Combination Therapy
2) By Cause Of Asthma: Allergic Asthma, Non-Allergic Asthma, Exercise-Induced Asthma, Occupational Asthma
3) By Severity: Mild Intermittent, Mild Persistent, Moderate Persistent, Severe Persistent
4) By Route Of Administration: Oral, Inhaled, Intravenous, Other Route Of Administration
5) By End-Users: Hospitals, Homecare, Specialty Clinics , Others End-Users

Subsegments:
1) By Controller Medications Inhaled Corticosteroids (ICS), Long-Acting Beta-Agonists (LABA), Leukotriene Receptor Antagonists (LTRA), Long-Acting Muscarinic Antagonists (LAMA), Methylxanthines
2) By Rescue Medications: Short-Acting Beta-Agonists (SABA), Systemic Corticosteroids, Anticholinergics
3) By Biologics: Anti-IGE Therapy, Anti-IL-5 Therapy, Anti-IL-4/IL-13 Therapy, Anti-TSLP Therapy
4) By Combination Therapy: ICS Or LABA Combinations, ICS Or LABA Or LAMA Combinations, ICS Or LAMA Combinations

Which Market Trends Are Expected to Dominate Asthma Disease Industry Growth?
In the asthma disease market, leading companies are concentrating on the development of solutions like monoclonal antibody therapies to improve the effectiveness of treatments and patient outcomes. Monoclonal antibody therapy is a type of targeted treatment that uses synthetic proteins created in a lab to imitate the immune system's ability to combat harmful pathogens, providing more accurate and efficient management of chronic diseases such as asthma. An example of this is the PANDA trial (preventing asthma in high-risk kids) that was launched by the National Institutes of Health (NIH), a medical research institution based in the US, in June 2022. The trial aims to test the use of the monoclonal antibody dupilumab in treating asthma among urban youth. This phase 2, randomized, placebo-controlled study aims to evaluate dupilumab's effectiveness on around 240 children, aged 6-17, living in urban areas with low income, who are suffering from poorly managed, type 2 inflammation, severe allergic asthma. The children will receive subcutaneous injections every two weeks for a year, along with regular asthma care, and are randomized 2:1 to either dupilumab or placebo. Moreover, the trial includes mechanistic research using nasal swabs and blood samples to study gene expression, particularly during respiratory viral infections, with the goal of understanding the molecular pathways of asthma exacerbations and how the treatment responds in this vulnerable pediatric population.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25701&type=smp

Which Companies Hold the Largest Market Share in the Asthma Disease Sector?
Major companies operating in the asthma disease market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Chiesi Farmaceutici S.p.A., Cipla Limited, Mundipharma International Limited, Generate Biomedicines.

Where Is the Asthma Disease Market Experiencing the Highest Growth?
North America was the largest region in the asthma disease market in 2024. The regions covered in the asthma disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.